The top five executives at Valeant Pharmaceuticals shared nearly US$123 million in compensation last year, up from US$23.8 million in 2013. Chairman and CEO Michael Pearson, who owns three per cent of the company with some 10 million shares, took the lowest compensation at US$10.28 million, while executive vice-president Ari Kellen topped the list at US$50.6 million, according to the company's proxy circular.